We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects.
- Authors
Karatrasoglou, Eleni A.; Dimou, Maria; Piperidou, Alexia; Lakiotaki, Eleftheria; Korkolopoulou, Penelope; Vassilakopoulos, Theodoros P.
- Abstract
Non-Hodgkin lymphoma's (NHL) incidence is rising over time, and B cell lymphomas comprise the majority of lymphomas. The phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homologue 1 (Akt)/mammalian target of the rapamycin (mTOR) signaling pathway plays a critical role in a variety of cellular processes, such as cell proliferation and survival. Its role in lymphomagenesis is confirmed in many different types of B cell lymphomas. This review is mainly focused on the PI3K/v-akt/mTOR pathway-related oncogenic mechanisms in B cell NHLs with an emphasis on common B cell lymphoma types [diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)]. Furthermore, it summarizes the literature regarding the clinical applications of the mTOR inhibitors temsirolimus and everolimus in B cell NHLs, which have been tested in a range of clinical trials enrolling patients with B cell malignancies, either as monotherapy or in combination with other agents or regimens.
- Subjects
B cell lymphoma; B cells; MANTLE cell lymphoma; PHOSPHATIDYLINOSITOL 3-kinases; DIFFUSE large B-cell lymphomas; ONCOGENES; MTOR inhibitors
- Publication
International Journal of Molecular Sciences, 2023, Vol 24, Issue 18, p14110
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms241814110